Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
DNA
Upturn stock ratingUpturn stock rating

Ginkgo Bioworks Holdings (DNA)

Upturn stock ratingUpturn stock rating
$9.46
Last Close (24-hour delay)
Profit since last BUY1.83%
upturn advisory
Consider higher Upturn Star rating
BUY since 11 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: DNA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $8.67

1 Year Target Price $8.67

Analysts Price Target For last 52 week
$8.67Target price
Low$5
Current$9.46
high$16.85

Analysis of Past Performance

Type Stock
Historic Profit -11.44%
Avg. Invested days 26
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 553.71M USD
Price to earnings Ratio -
1Y Target Price 8.67
Price to earnings Ratio -
1Y Target Price 8.67
Volume (30-day avg) 6
Beta 1.26
52 Weeks Range 5.00 - 16.85
Updated Date 06/30/2025
52 Weeks Range 5.00 - 16.85
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -8.91

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-06-13
When Before Market
Estimate -0.08
Actual -1.68

Profitability

Profit Margin -198.84%
Operating Margin (TTM) -182.09%

Management Effectiveness

Return on Assets (TTM) -16.99%
Return on Equity (TTM) -57.76%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 471350555
Price to Sales(TTM) 2.33
Enterprise Value 471350555
Price to Sales(TTM) 2.33
Enterprise Value to Revenue 1.99
Enterprise Value to EBITDA -1.79
Shares Outstanding 46344600
Shares Floating 40286320
Shares Outstanding 46344600
Shares Floating 40286320
Percent Insiders 6.88
Percent Institutions 79.41

Analyst Ratings

Rating 3
Target Price 8.67
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 1
Sell 3
Strong Sell 1
Strong Sell 1

ai summary icon Upturn AI SWOT

Ginkgo Bioworks Holdings

stock logo

Company Overview

overview logo History and Background

Ginkgo Bioworks Holdings, Inc. was founded in 2008. It went public in 2021 via a SPAC merger with Soaring Eagle Acquisition Corp. Ginkgo's core mission is to make biology easier to engineer, enabling applications across diverse industries.

business area logo Core Business Areas

  • Foundry Services: Ginkgo's foundry offers a platform for designing and engineering organisms for various applications, from creating novel enzymes to producing sustainable materials.
  • Cell Engineering: Ginkgo specializes in engineering cells to perform specific functions, such as producing biofuels, pharmaceuticals, and other high-value products.
  • Biosecurity: Through Concentric by Ginkgo, the company provides biosecurity solutions, including pathogen monitoring and outbreak response, to help prevent and mitigate the spread of infectious diseases.

leadership logo Leadership and Structure

Ginkgo Bioworks is led by CEO Jason Kelly. The organizational structure includes teams focused on foundry operations, software development, strain engineering, biosecurity, and commercial partnerships.

Top Products and Market Share

overview logo Key Offerings

  • Foundry Platform: Ginkgo's main offering is its foundry platform, which allows customers to design and engineer organisms. The market share is difficult to ascertain precisely due to the nascent nature of the synthetic biology market. Competitors include Amyris and Zymergen (now part of Ginkgo).
  • Concentric (Biosecurity): Concentric provides biosecurity services, including COVID-19 testing and pathogen monitoring. Market share is competitive with companies like Illumina and Roche offering similar testing services.

Market Dynamics

industry overview logo Industry Overview

The synthetic biology industry is rapidly growing, driven by increasing demand for sustainable and bio-based products. It encompasses areas like biopharmaceuticals, agriculture, and industrial biotechnology.

Positioning

Ginkgo is a leading player in the synthetic biology market, offering a platform for cell programming. Its competitive advantage lies in its scale, breadth of capabilities, and data assets.

Total Addressable Market (TAM)

The TAM for synthetic biology is estimated to be in the hundreds of billions of dollars. Ginkgo is positioning itself to capture a significant portion of this market by offering a comprehensive platform for cell engineering.

Upturn SWOT Analysis

Strengths

  • Leading platform for cell programming
  • Extensive data assets and expertise
  • Diverse customer base
  • Strategic acquisitions
  • Strong intellectual property portfolio

Weaknesses

  • High operating expenses
  • Dependence on key partners
  • Unproven profitability at scale
  • Complexity of the technology

Opportunities

  • Expanding applications of synthetic biology
  • Increasing demand for sustainable products
  • Partnerships with established companies
  • Government funding and support
  • Advancements in AI and automation

Threats

  • Competition from other synthetic biology companies
  • Regulatory hurdles
  • Ethical concerns
  • Economic downturns
  • Technological disruptions

Competitors and Market Share

competitor logo Key Competitors

  • DNA
  • AMRS
  • TMO

Competitive Landscape

Ginkgo's advantage is its horizontal platform approach, while competitors may focus on specific applications. Challenges include scaling production and demonstrating profitability.

Major Acquisitions

Zymergen

  • Year: 2022
  • Acquisition Price (USD millions): 300
  • Strategic Rationale: Expanded Ginkgo's capabilities in strain engineering and data assets, and eliminated a key competitor.

Growth Trajectory and Initiatives

Historical Growth: Ginkgo has experienced rapid growth in revenue and customer base since its founding.

Future Projections: Analyst estimates suggest continued revenue growth for Ginkgo, driven by increased adoption of its platform.

Recent Initiatives: Ginkgo has focused on expanding its foundry capabilities, forming strategic partnerships, and developing new biosecurity solutions.

Summary

Ginkgo Bioworks is a leading company in the synthetic biology space, offering a comprehensive platform for cell engineering. Its strengths include its extensive data assets, strategic acquisitions, and diverse customer base. Challenges include high operating expenses and achieving profitability at scale. Future growth depends on expanding applications of synthetic biology and forming strategic partnerships.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company reports
  • Analyst estimates
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are approximate and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Ginkgo Bioworks Holdings

Exchange NYSE
Headquaters Boston, MA, United States
IPO Launch date 2021-04-19
Founder, CEO & Director Dr. Jason Kelly Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 834
Full time employees 834

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.